Macomics and Ono Pharmaceutical link up on cancer targets

23 March 2023

UK immune-oncology company Macomics has entered into a worldwide drug discovery collaboration with Japan’s Ono Pharmaceutical (TYO: 4528) to develop new antibody drugs against a novel macrophage target of interest in cancer.

Shares of the Japanese company closed down 3% at 2,712 yen following the announcement.

As per the accord, Macomics will identify and characterize antibody candidates against the novel target of interest using its ENIGMAC macrophage drug discovery platform. For its part, Ono will have an exclusive option to license global rights to the candidates for further development and commercialization. Macomics will receive an undisclosed up-front payment, R&D funding, and success-based milestone payments, as well as tiered royalties based on global net sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK